425: Palvella Therapeutics Announces First Patient Dosed in Phase 3 Trial of QTORIN for Microcystic Lymphatic Malformations

Palvella Therapeutics has dosed the first patient in its Phase 3 clinical trial, SELVA, evaluating QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations (microcystic LMs).

Summary

• Palvella Therapeutics has initiated its Phase 3 clinical trial, SELVA, to assess the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for treating microcystic lymphatic malformations (microcystic LMs).
• The first patient has been dosed in the multicenter trial.
• Microcystic LMs is a rare, genetic skin disease affecting an estimated more than 30,000 diagnosed patients in the U.S.
• The SELVA trial is a single-arm, baseline-controlled study where QTORIN rapamycin is administered topically once daily.
• The primary endpoint is the change from baseline in the overall microcystic LM Investigator Global Assessment (mLM-IGA) at week 24.
• The trial aims to enroll approximately 40 participants, ages six and older, at leading vascular anomaly centers across the U.S.
• QTORIN rapamycin has received Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA.
• Palvella received up to $2.6 million from the FDA's Office of Orphan Products Development to support the SELVA study.
• Palvella and Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS) announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction in July 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the advancement of a potential treatment for a rare disease into Phase 3 clinical trials, the receipt of FDA designations, and the potential for commercialization. However, the inherent risks associated with clinical development temper the overall sentiment.

Positives

• Initiation of Phase 3 trial represents significant progress in developing a potential treatment for microcystic LMs.
• QTORIN rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs.
• FDA's Breakthrough Therapy, Fast Track, and Orphan Drug Designations could expedite the development and review process.
• Funding from the FDA's Office of Orphan Products Development supports the SELVA study.
• The merger agreement with Pieris Pharmaceuticals could provide additional resources and expertise.

Negatives

• The trial is still in Phase 3, and there is no guarantee of positive results or regulatory approval.
• Microcystic LMs is a rare and complex disease, which could pose challenges in clinical development.
• The trial has a relatively small sample size of approximately 40 participants.

Risks

• The Phase 3 trial may not yield positive results, leading to failure to obtain regulatory approval.
• Adverse events or safety concerns could arise during the trial, impacting the development of QTORIN rapamycin.
• The merger with Pieris Pharmaceuticals may not be completed or may not provide the anticipated benefits.
• Competitors may develop alternative treatments for microcystic LMs.
• The market for QTORIN rapamycin may be smaller than anticipated.

Future Outlook

Palvella aims to advance QTORIN rapamycin to potential regulatory approvals and U.S. commercialization.

Management Comments

• Joyce M. Teng, M.D., Ph.D., stated that microcystic LMs can result in significant morbidity beginning in childhood and have a lifelong impact.
• Wes Kaupinen, Founder and CEO of Palvella, expressed pleasure in dosing the first patient in the Phase 3 SELVA trial, an important milestone towards potential regulatory approvals and U.S. commercialization.

Industry Context

This announcement highlights the ongoing efforts to develop treatments for rare genetic skin diseases with unmet medical needs, reflecting a broader trend in the biopharmaceutical industry towards orphan drug development.

Comparison to Industry Standards

• It is difficult to compare Palvella's progress directly to industry standards without knowing the specific details of other companies' clinical trials for similar conditions.
• However, the receipt of Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA suggests that QTORIN rapamycin has shown promising early results compared to other potential treatments.
• Companies like BioMarin Pharmaceutical and Alexion Pharmaceuticals are known for their work in rare diseases, and Palvella's approach aligns with their focus on developing targeted therapies for underserved patient populations.

Stakeholder Impact

• Positive impact on patients suffering from microcystic LMs, as QTORIN rapamycin has the potential to be the first approved therapy.
• Potential benefits for Palvella's shareholders, if QTORIN rapamycin is successfully commercialized.
• Potential impact on Pieris Pharmaceuticals' shareholders, pending completion of the merger.
• Positive impact on vascular anomaly centers across the U.S., as they will be involved in the SELVA trial.

Next Steps

• Enrollment and completion of the Phase 3 SELVA clinical trial.
• Analysis of the trial results.
• Submission of a New Drug Application (NDA) to the FDA, assuming positive trial results.
• Potential commercialization of QTORIN rapamycin in the U.S., pending regulatory approval.

Key Dates